BioCardia, Inc.
US ˙ NasdaqCM ˙ US09060U5074

Introduction

This page provides a comprehensive analysis of the known insider trading history of David McClung. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David McClung has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:BCDA / BioCardia, Inc. Chief Financial Officer 47,950
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David McClung. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases BCDA / BioCardia, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BCDA / BioCardia, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2025-06-30 BCDA McClung David 4,819 2.0750 4,819 2.0750 9,999 10 2.4200 1,663 16.63
2025-04-23 BCDA McClung David 13,123 1.9050 13,123 1.9050 24,999
2022-10-10 BCDA;BCDAW McClung David 2,000 2.0700 133 31.0500 4,140
2018-11-05 BCDA McClung David 1,600 2.5640 133 30.7680 4,102
2018-10-12 BCDA McClung David 500 2.6360 42 31.6320 1,318
2018-09-25 BCDA McClung David 2,850 2.4520 238 29.4240 6,988
2018-03-22 BCDA McClung David 500 1.9000 42 22.8000 950
2018-03-21 BCDA McClung David 750 1.9000 62 22.8000 1,425

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BCDA / BioCardia, Inc. Insider Trades
Insider Sales BCDA / BioCardia, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BCDA / BioCardia, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BCDA / BioCardia, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David McClung as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-07-02 2025-06-30 4 BCDA BioCardia, Inc.
Common Stock
P - Purchase 4,819 47,950 11.17 2.08 9,999 99,496
2025-04-25 2025-04-23 4 BCDA BioCardia, Inc.
Common Stock
P - Purchase 13,123 43,131 43.73 1.90 24,999 82,165
2024-10-16 2024-10-11 4 BCDA BioCardia, Inc.
Common Stock
F - Taxes -11,565 30,008 -27.82 2.65 -30,647 79,521
2024-10-16 2024-10-11 4 BCDA BioCardia, Inc.
Common Stock
A - Award 24,193 41,573 139.20 2.65 64,111 110,168
2024-09-05 2024-09-03 4 BCDA BioCardia, Inc.
Common Stock
A - Award 8,333 17,380 92.11 3.00 24,999 52,140
2023-06-26 2023-06-23 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
A - Award 4,280 135,724 3.26 2.34 9,998 317,051
2023-06-02 2023-05-31 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
F - Taxes -20,676 131,444 -13.59 1.77 -36,597 232,656
2023-05-22 2023-05-18 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
A - Award 61,389 152,120 67.66 1.70 104,361 258,604
2023-04-07 2022-05-12 4/A BCDA;BCDAW BioCardia, Inc.
Common Stock
A - Award -17,347 79,803 -17.86 1.32 -22,898 105,340
2022-12-19 2022-12-16 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
A - Award 8,928 87,446 11.37 1.68 14,999 146,909
2022-10-11 2022-10-10 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
P - Purchase 2,000 78,518 2.61 2.07 4,140 162,532
2022-05-18 2022-05-12 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
F - Taxes -20,632 76,518 -21.24 1.32 -27,234 101,004
2022-04-18 2022-04-14 4 BCDA;BCDAW BioCardia, Inc.
Stock Option (right to buy)
A - Award 60,000 60,000
2022-04-18 2022-04-14 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
A - Award 50,345 97,150 107.56
2021-06-11 2021-06-10 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
F - Taxes -7,274 46,805 -13.45 4.35 -31,642 203,602
2021-04-27 2021-04-21 4 BCDA;BCDAW BioCardia, Inc.
Stock Option (right to buy)
A - Award 75,850 75,850
2021-04-27 2021-04-21 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
A - Award -21,370 54,079 -28.32
2020-07-01 2020-06-30 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
F - Taxes -7,895 32,709 -19.44 2.40 -18,948 78,502
2020-04-29 2020-04-24 4/A BCDA;BCDAW BioCardia, Inc.
Common Stock
A - Award 19,312 40,604 90.70
2020-04-28 2020-04-24 4 BCDA;BCDAW BioCardia, Inc.
Stock Option (right to buy)
A - Award 25,540 25,540
2020-04-28 2020-04-24 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
A - Award 19,312 21,292 975.35
2020-03-27 2020-03-11 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
F - Taxes -2,582 21,292 -10.82 3.60 -9,295 76,651
2020-03-27 2019-08-27 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
A - Award 6,315 23,874 35.96
2019-08-08 2019-08-06 4 BCDA;BCDAW BioCardia, Inc.
Warrant (right to buy)
P - Purchase 16,871 16,871
2019-08-08 2019-08-06 4 BCDA;BCDAW BioCardia, Inc.
Convertible promissory note
C - Conversion
2019-08-08 2019-08-06 4 BCDA;BCDAW BioCardia, Inc.
Common Stock
C - Conversion 16,871 23,071 272.11 3.00 50,613 69,213
2019-08-08 2019-07-05 4 BCDA;BCDAW BioCardia, Inc.
Convertible promissory note
P - Purchase 50,000.00
2018-11-07 2018-11-05 4 BCDA BioCardia, Inc.
Common Stock
P - Purchase 1,600 6,200 34.78 2.56 4,102 15,897
2018-10-16 2018-10-12 4 BCDA BioCardia, Inc.
Common Stock
P - Purchase 500 4,600 12.20 2.64 1,318 12,126
2018-09-25 2018-09-25 4 BCDA BioCardia, Inc.
Common Stock
P - Purchase 2,850 4,100 228.00 2.45 6,988 10,053
2018-03-22 2018-03-21 4 BCDA BioCardia, Inc.
Common Stock
P - Purchase 750 750 1.90 1,425 1,425
2018-03-22 2018-02-01 4 BCDA BioCardia, Inc.
Stock Option (right to buy)
A - Award 159,020 159,020
2018-03-22 2018-03-22 4 BCDA BioCardia, Inc.
Common Stock
P - Purchase 500 1,250 66.67 1.90 950 2,375
2016-10-26 3 BCDA BioCardia, Inc.
No securities beneficially owned
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)